Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Investor Presentation (July 2021)
25 slides from Genetic Technologies's investor presentation, Jul 28, 2021
Slide 1: Investor Presentation and Webinar
Investor Presentation and Webinar Melbourne, Australia, 28 July 2021: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), a diversified Genomics and AI driven preventative health business provides the attached presentation and advises that the Company will be providing the following we
Slide 2: Investor Relations / About Genetic Technologies Limited
Investor Relations (AUS) Investor Relations and Media (US) Stephanie Ottens Dave Gentry Market Eye 1 800 RED CHIP (733 2447) M: +61 434 405 400 Cell: 407 491 4498 E: stephanie.ottens@marketeye.com.au E: dave@redchip.com About Genetic Technologies Limited Genetic Technologies Limited (ASX: GTG; Nasda
Slide 3: Investor Update
Investor Update July 2021 Authorised by the Board of Directors of Genetic Technologies Limited ASX: GTG NASDAQ: GENE
Slide 4: Notice: Forward looking statements
Notice: Forward looking statements The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may require fu
Slide 5: Our Overview
Our Overview 01 02 03 04 05 06 Our Vision & Our Markets Our Channels & Our Portfolio & Our Acquisition Our Capabilities Values Divisions Innovation 2021 Overview Prioritising the Focused on three Executing through cutting EasyDNA - Building our Building our internal Where are market entry distinct a
Slide 6: Our Vision & Values
Our Vision & Values To be the world’s leader in personalised predictive genetics Collaborative Dynamic Cooperative, Receptive, Proactive, Striving, Informative, Transparent Responsive, Motivated. Unity and diversity drives us to make a Cutting edge Innovation that creates positive impact on the comm
Slide 7: Our 2021 Snapshot
Our 2021 Snapshot Multi-year distribution agreement License and distribution agreement for COVID-19 A$21 million Risk Test with IBX for minimum of US$2.9 million over 3 years to maintain exclusivity Strong cash balance with 24 month runway2 Launched CIT in USA & AUS for other tests1 Strong focus on
Slide 8: Our Markets and Collaborators
Our Markets and Collaborators United States Europe & UK Asia Australia & New Zealand (Inc. SEA, China and India) geneType® Polygenic Risk Commencing CE certification H2 CY2021 to commenced a Certification by Australian Score (PRS) tests for breast, enabling EU launch of Novel scoping and Prioritisin
Slide 9: Our Pathways
Our Pathways Medical – Business to Business Consumer initiated testing (CIT) Direct to consumer testing (DTC) (B2B) with medical supervision with no medical supervision A communication Certifying Launched US and Current products Recent Acquisition Provides Genetic and execution plan reimbursable Aus
Slide 10: Our Channels – B2B
Our Channels – B2B Business to business sales via the medical profession • Adversely impacted by COVID-19 restrictions but Third Party Licensing remains a key avenue for education and sales Provides enhanced distribution and product • Combined with an educational program to target offering via: heal
Slide 11: Our Divisions
Our Divisions Emerging divisions Pharmoco- Oncology Genetics & Existing divisions BC, CRC, PC, Companion NEW – Universal collection test Kit Melanoma diagnostics To support Multi Test Launch CVD Germline testing (Heart Disease) BRCA, Lynch IHD, AF Syndrome and Somatic testing COVID-19 Mental Health
Slide 12: Our Innovation
Our Innovation geneType integrates genetic risk and clinical risk to better stratify individual risk. Patients with potentially high risk may exceed actionable clinical guidelines 10 – 15 years earlier than those with low risk 1,2,3 Breast Cancer (BC)1 Colorectal Cancer (CRC)2 Chronic Heart Disease
Slide 13: Our Portfolio – Driving Growth
Our Portfolio − Driving Growth ` ` Moderate CIT Platform in AUS and Revenue USA selling BRC and CRC Expectations Q2 CY 2021 IBX COVID Risk Test Revenue released for sale May 31, Commenced 2021 Q2 CY 2021 Expanding into reimbursable 100% Germline + PRS space test for Breast Cancer Revenue Expectation
Slide 14: Significant market opportunity
Significant market opportunity To provide predictive, pre-symptomatic testing to inform lifestyle choices and healthcare discussions Near Term Addressable Market GTG Target Market for BRCA Panel + Breast Cancer PRS 281,5505 1st degree Testing Diagnosis of breast cancer providing up to 100% genetic a
Slide 15: Our Innovation - Multi Test
Our Innovation - Multi Test One test to help identify risk of serious disease for up to 70% of Mortalities and Morbidities Committed to continually invest in developing multi population testing solutions GeneType Multi-test to include Oncology >70% of mortality & morbidity Breast Cancer Colorectal C
Slide 16: EasyDNA – Acquisition of DTC Platform
EasyDNA – Acquisition of DTC Platform • This acquisition provides Genetic Technologies the foundation to grow in 40 countries with an extensive DTC market channel • Agreements with 12 laboratories in North America, AsiaPac and Europe • EasyDNA currently sells paternity, oncology and health and wellb
Slide 17: Our Capability
Our Capability Dedicated Innovation Hub Developing and capturing the next generation of innovation in genomics Marketing and Positioning Enhanced Sales and Distribution Creating a consumer and patient led Capitalise on Licensing, JV and M&A opportunities infrastructure for a direct to consumer Partn
Slide 18: Our Summary
Our Summary 01 02 03 04 05 06 Our Vision and Our Markets Our Channels & Our Portfolio & Our Acquisition Our Capabilities Values Divisions Innovation Targeted and Focused and Cutting edge Positioned for Aligned to deliberate distinct innovation growth execute 16
Slide 19: Thank you
Thank you
Slide 20: Appendices
Appendices
Slide 21: Our Intellectual Property
Our Intellectual Property 7 Patents granted in the US 9 Patent families pending • Patent 11,031,098, Computer systems and methods for genomic analysis • Methods for breast cancer risk assessment • Patent 10,683,549, Methods for assessing risk of developing breast cancer • Methods for assessing risk
Slide 22: Board and Management: Sales and Scientific expertise leading GTG
Board and Management: Sales and Scientific expertise leading GTG Mr. Peter Rubinstein Dr. Lindsay Wakefield Mr Nick Burrows BEc, LLB MBBS B.Com, FAICD, FCA, Chairman - Non – Executive Non – Executive Director FGIA, FTIA, F Fin Director Non – Executive Director Dr. Jerzy “George” Muchnicki Erika Spae
Slide 23: Strong Scientific Leadership: Advisory Board
Strong Scientific Leadership: Advisory Board Professor Jon Emery Professor Finlay Macrae AO Ora K. Gordon, M.D. MBBCh MA DPhil FRACGP MRCGP MBBS, MD, FRACP, FRCP, AGAF MD, MS, FACMG Research & Education Lead, Primary MWGO is Principal Fellow and Regional Medical Director, Center for Care Integration
Slide 24: Corporate Overview
Corporate Overview Top 50 share registry breakdown Dual Listed on the ASX and Nasdaq Financial Information Other, 21% Share price (AUD) as at 26 July 2021 0.8c ADR price (USD) as at 26 July 2021 $3.66 Board and Management , Ord Share on Issue (M) 9,017 7% ASX 52-week trading (low/high) 0.6/1.4c Nasd
Slide 25: Defined Terms
Defined Terms Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease. Polygenic risk score - a number associated
Genetic Technologies — Investor Presentation (July 2021) on 6ix